Tilray Medical recently shared promising results from a study examining the effectiveness of oral cannabis extract in reducing chemotherapy-induced nausea and vomiting (CINV) for cancer patients. In this randomized, placebo-controlled trial, 147 participants were given capsules with 2.5 mg of THC and 2.5 mg of CBD, or a placebo, three times daily over six days. The study ran from 2016 to 2022 and targeted patients who continued to experience CINV despite standard anti-nausea treatments. Results showed a significant improvement: 24% of participants on the cannabis extract had no vomiting or need for extra medication, compared to only 8% on the placebo.

In addition to reduced nausea and fewer vomiting episodes, patients using the cannabis extract reported some side effects, such as increased sedation (18% compared to 7% in the placebo group), dizziness (10% versus 0%), and mild, temporary anxiety (4% versus 1%). Denise Faltischek, Tilray’s Chief Strategy Officer, expressed optimism about the findings, emphasizing the potential for cannabinoids to improve quality of life for chemotherapy patients. Faltischek noted that the study reflects Tilray’s commitment to advancing medical research and improving patient care, especially for those facing difficult treatments.

As a global leader in medical cannabis, Tilray Medical has built a reputation for supporting medical cannabis research worldwide. The company supplies cannabis products to over 20 countries, serving patients, physicians, and medical institutions with EU-GMP-certified products.